DC Field | Value | Language |
dc.contributor.author | Ursan, Mariana | - |
dc.date.accessioned | 2020-10-05T08:54:01Z | - |
dc.date.available | 2020-10-05T08:54:01Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | URSAN, Mariana. Mechanisms of venous thromboembolism in oral contraception. In: MedEspera: the 8th Internat. Medical Congress for Students and Young Doctors: abstract book. Chișinău: S. n., 2020, p. 263. | en_US |
dc.identifier.uri | https://medespera.asr.md/wp-content/uploads/ABSTRACT-BOOK.pdf | - |
dc.identifier.uri | http://repository.usmf.md/handle/20.500.12710/11924 | - |
dc.description | Department of Biochemistry and
Clinical Biochemistry, Nicolae Testemitanu State University of Medicine and Pharmacy,
Chisinau, Republic of Moldova, The 8th International Medical Congress for Students and Young Doctors, September 24-26, 2020 | en_US |
dc.description.abstract | Introduction. Combined oral contraceptives (COC) are more and more used by fertile women,
as well as teenagers in different cases, like dysmenorrhea, endometriosis, ovarian polycystic
syndrome, dysfunctional uterine bleeding (DUB) and hormone-replacement therapy (HRT) for
primary ovarian insufficiency. Even if they act efficiently in pregnancy prevention and
hormonal regulation, they also significantly increase the risk of venous thromboembolism.
Recent researches have shown that the risk of venous thromboembolism depends a lot on the
ratio of estrogen/progestin in combined oral contraceptives and on thrombotic events of women
on COC.
Aim of the study. Description of the mechanisms that can induce venous thromboembolism
and the selection of women potentially predisposed to them. Highlighting the frequency of their
occurrence depending on the ratio estrogen/progestin in the composition of combined oral
contraceptive. Individual prescription for oral contraceptives, in order to reduce their risk for
health.
Materials and methods. The literature analysis has been conducted using 98 bibliographic
sources from PubMed search engine starting with January 2017 and from PMC since January
2015.
Results. In women with mutation of Factor V Leiden and prothrombin, as well as defects of
antithrombin III, protein C and S, that take hormonal contraceptives, the risk of venous
thromboembolism increases up to 3-9%, unlike women who do not take them. Also, women
who take oral contraceptives with estrogen and levonorgestrel, deriving from progestin, have
a high level of Factor VII, X and fibrinogen, produced by high hepatic synthesis stimulated by
the first hepatic degradation of estrogen, and high APC resistance and low level of
antithrombine and protein S. Thus, favorable conditions for venous thromboembolism occur.
Conclusions. In women who take oral contraceptives the risk of thrombosis is higher than in
women who do not take them. The mechanisms inducing venous thromboembolism depend a
lot on the specific ratio of estrogen/progestin and the presence of hereditary or acquired
thrombophilia in women on COC. | en_US |
dc.language.iso | en | en_US |
dc.publisher | MedEspera | en_US |
dc.subject | oral contraceptives | en_US |
dc.subject | venous thromboembolism | en_US |
dc.subject | hormones | en_US |
dc.subject | thrombophilia | en_US |
dc.title | Mechanisms of venous thromboembolism in oral contraception | en_US |
dc.type | Article | en_US |
Appears in Collections: | MedEspera 2020
|